Signal Clearmind's MEAI candidate is named in US veterans legislation and enters Yale and Johns Hopkins trials

Summary

The Psychedelics and Healing Initiative highlights MEAI, also called 5-MeO-AI, a candidate from Clearmind Medicine for alcohol use disorder. The compound is a neuroplastogen designed to work without producing hallucinations. It was recently named in bipartisan federal legislation in the US aimed at supporting the health of veterans. Clearmind is led by Adi Zuloff-Shani, described as the only woman chief executive of a psychedelic biopharma company. FDA-approved clinical trials of MEAI at the Yale School of Medicine and the Johns Hopkins School of Medicine have begun to report positive results. The Initiative uses the case to show neuroplastogens gaining both political and clinical footing.